STUDI PENGGUNAAN LAKTULOSA PADA PASIEN SIROSIS HATI DENGAN HEPATIK ENSEFALOPATI (Penelitian Dilakukan di Rumah Sakit Umum Daerah Sidoarjo)
Daftar Isi:
- Background : Hepatic Encephalophaty is a neuropsychiatric syndrome occuring in patient with cirrhosis characterized by pugnacious, memory and conscious impairment to coma. Hepatic encephalophaty is caused by brain toxicity of impaired detoxification of ammonia due to liver dysfunction. Lactulose as single or combination use has benefit to prevent and improve hepatic encephalophaty. Lactulose reduce blood ammonia by decrease it’s absorption and increase elimination through feces. Objective : To identify the pattern of lactulose use in cirrhosis patients with hepatic encephalophaty in Regional Public Hospital of Sidoarjo. Method : Observational descriptive and retrospective design in cirrhosis patients with hepatic encephalophaty period June 2016-june 2019. Result & Conclusion : The patern of lactulose is in single use for 6 patients (32%) and combination for 13 patients (68%). Single lactulose therapy that mostly used was (3x10g) orally by 5 patients (83%) and for combination was Lactulose (3x20g) orally + Comafusin® hepar (12,5g BCAA) intravenous by 5 patient (39%).